$2.93 -0.02 (-0.68%)
Artiva Biotherapeutics, Inc. Common Stock (ARTV)
Artiva Biotherapeutics, Inc. is a biotechnology company focused on developing off-the-shelf natural killer (NK) cell therapies for cancer treatment. The company aims to leverage its proprietary platforms to create innovative immunotherapies that enhance the body's immune response against tumors. Founded with a focus on advancing cell therapy technologies, Artiva is dedicated to addressing unmet needs in oncology.
Company News
NK Cell Therapy Market on Track for Exponential Growth Amid Rising Pipeline Developments | DelveInsight
The NK cell therapy market is experiencing significant growth, driven by rising interest in immuno-oncology and advancements in cell engineering technologies. Key players are investing in innovative approaches, including combination therapies and gene-modified NK cells, to improve clinical outcomes.